PD-1

27 registered clinical trials studyying PD-1 — 15 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With NCT07128251	Anhui Provincial Hospital	Phase 2
Not Yet Recruiting	A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injec NCT07131501	The First Affiliated Hospital with Nanjing Medical University	Phase 2
Not Yet Recruiting	PD-1 Inhibitor Therapy Versus Radiotherapy in MPR Patients With Locally Advanced HNSCC After Neoadjuvant Immun NCT07090707	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 2
Not Yet Recruiting	A Prospective Study: the Impact of Sleep Disturbances on Immunotherapy in Patients With Lung Cancer NCT06953765	Shanghai Zhongshan Hospital	—
Not Yet Recruiting	Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer NCT06888037	Ruijin Hospital	Phase 2
Recruiting	Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Ad NCT07035002	Ruijin Hospital	Phase 1
Active Not Recruiting	Tirellizumab Combined With TP Neoadjuvant Therapy in the Treatment of Early Oral Squamous Cell Carcinoma （HNC- NCT07267286	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 2
Recruiting	HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of NCT06632093	First Hospital of China Medical University	—
Recruiting	A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Ma NCT06635954	Oxford Biodynamics Inc.	—
Recruiting	LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT06479759	Shanghai Pulmonary Hospital, Shanghai, China	Phase 2
Recruiting	Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004) NCT06130332	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 2
Unknown	RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC NCT05979740	RenJi Hospital	Phase 2
Recruiting	4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvan NCT05980702	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 2
Unknown	A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metasta NCT05741021	Shandong New Time Pharmaceutical Co., LTD	Phase 2
Recruiting	PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immun NCT05980715	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 3
Completed	Biomarker Analysis of Tislelizumab Combined With Chemotherapy for Perioperative Treatment of G/GEJ Adenocarcin NCT05508399	Xijing Hospital	—
Unknown	PD-1 Antibody for Reactive EBV After BMT NCT04690036	Beijing Friendship Hospital	EARLY_Phase 1
Recruiting	Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors NCT04615988	Icahn School of Medicine at Mount Sinai	—
Active Not Recruiting	Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer NCT04906044	The First Hospital of Jilin University	Phase 1
Unknown	A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislel NCT04814069	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University	Phase 2
Unknown	Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction NCT06250894	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Phase 2
Recruiting	Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma NCT04778956	Sun Yat-sen University	Phase 3
Recruiting	Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Sintilimab in Clinica NCT04840355	Guohui Li	—
Unknown	PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC NCT04284202	The Affiliated Hospital of Qingdao University	Phase 2
Unknown	Genetic Mutation in Recurrent Cervical Cancer NCT04191226	Lei Li	—
Unknown	Genetic Mutation in Epithelial Ovarian Cancer NCT04191252	Lei Li	—
Unknown	Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ NCT04061928	Peking University	Phase 1 / Phase 2